camptothecin has been researched along with diflomotecan in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (82.35) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bailly, C; Baroggi, N; Bigg, DC; Camara, J; Cazaux, JB; Coulomb, H; Demarquay, D; Huchet, M; Lanco, C; Lavergne, O; Le Breton, C; Manginot, E; Muller, N; Rolland, A | 1 |
| Huang, Q; Lu, W; Wang, L | 1 |
| Bailly, C; Bigg, DC; Camara, J; Coulomb, H; Demarquay, D; Huchet, M; Kasprzyk, PG; Lavergne, O; Lesueur-Ginot, L | 1 |
| Bigg, DC; Chyzak, G; Gilbert, C; Larsen, AK; Lavergne, O; Lesueur-Ginot, L; Naguibneva, I; Plisov, SY | 1 |
| Bailly, C; Bal, C; Bigg, DC; Demarquay, D; Facompré, M; Hildebrand, MP; Lansiaux, A; Lavergne, O; Wattez, N | 1 |
| Maneely, D | 1 |
| de Jonge, MJ; Devlin, M; Gelderblom, H; Obach, R; Pentheroudakis, G; Principe, P; Pruñonosa, J; Salazar, R; Seguy, F; Twelves, C; van Hooije, C; Verweij, J | 1 |
| Osheroff, N | 1 |
| Ahluwalia, R; Gelderblom, H; Marsh, S; McLeod, HL; Obach, R; Principe, P; Sparreboom, A; Twelves, C; Verweij, J | 1 |
| Cendrós, JM; Garrido, MJ; Obach, R; Peraire, C; Principe, P; Segura, C; Trocòniz, IF | 1 |
| Althaus, M; Diolez, C; Manginot, E; Peters, R; Rolland, A; Veyrat, M | 1 |
| de Jonge, MJ; McGovern, D; Obach, R; Principe, P; Scott, L; Soepenberg, O; Th Planting, AS; Twelves, C; Verweij, J | 1 |
| Bates, SE; Guirouilh-Barbat, J; Liao, Z; Polgar, O; Pommier, Y; Robey, RW; To, KK | 1 |
| Cendros, JM; Evans, TR; Falk, S; Graham, JS; Samuel, LM | 1 |
| Gelderblom, H; Kroep, JR | 1 |
| Beijnen, JH; Cendrós, JM; Friberg, LE; Huitema, AD; Karlsson, MO; Keizer, RJ; Obach, R; Peraire, C; Schellens, JH; Soto, E; Trocóniz, IF; Wanders, J | 1 |
| Buil-Bruna, N; Garrido, MJ; Mangas-Sanjuan, V; Soto, E; Trocóniz, IF | 1 |
3 review(s) available for camptothecin and diflomotecan
| Article | Year |
|---|---|
Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2013 |
Diflomotecan. Ipsen.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Drugs, Investigational; Enzyme Inhibitors; Humans; Neoplasms; Topoisomerase I Inhibitors | 2004 |
Diflomotecan, a promising homocamptothecin for cancer therapy.
Topics: Animals; Camptothecin; Clinical Trials as Topic; Humans; Neoplasms; Treatment Outcome | 2009 |
4 trial(s) available for camptothecin and diflomotecan
| Article | Year |
|---|---|
Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms | 2003 |
Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; France; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Multicenter Studies as Topic; Neoplasms; Neutropenia | 2006 |
A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Administration Schedule; Enzyme Inhibitors; Europe; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Treatment Outcome | 2007 |
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Discovery; Female; Humans; Leukocyte Count; Male; Middle Aged; Models, Biological; Neutropenia; Predictive Value of Tests; Sulfonamides; Treatment Outcome | 2011 |
10 other study(ies) available for camptothecin and diflomotecan
| Article | Year |
|---|---|
Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins.
Topics: Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; HT29 Cells; Humans; Inhibitory Concentration 50; Stereoisomerism; Tumor Cells, Cultured | 2000 |
The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Cell Division; Cell-Free System; DNA; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Drug Stability; Enzyme Inhibitors; Female; Humans; Male; Mice; Mice, Nude; Osteonectin; Prostatic Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Caco-2 Cells; Camptothecin; Cell Division; Colonic Neoplasms; DNA Topoisomerases, Type I; DNA, Superhelical; Growth Inhibitors; HT29 Cells; Humans; Kinetics; Multidrug Resistance-Associated Proteins; Spheroids, Cellular; Tumor Cells, Cultured | 2001 |
Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspases; Cell Cycle; Cell Survival; DNA Fragmentation; Endocytosis; Enzyme Activation; HL-60 Cells; Humans; Hydrogen-Ion Concentration; Membrane Potentials; Mitochondria; Phosphatidylserines; Proto-Oncogene Proteins c-bcl-2 | 2001 |
Clinical Trials in Cancer-SMi Conference. 11-12 June 2003, London, UK.
Topics: Antineoplastic Agents; Camptothecin; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Humans; Molecular Structure; Neoplasms; Quinazolines; Treatment Outcome | 2003 |
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Female; Genotype; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasm Proteins | 2004 |
Practical formal total syntheses of the homocamptothecin derivative and anticancer agent diflomotecan via asymmetric acetate aldol additions to pyridine ketone substrates.
Topics: Aldehydes; Antineoplastic Agents; Camptothecin; Heterocyclic Compounds, 4 or More Rings; Ketones; Pyridines | 2006 |
Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.
Topics: Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Glioblastoma; Humans; Topoisomerase I Inhibitors | 2008 |
A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Breath Tests; Camptothecin; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Erythromycin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Survival Rate; Tissue Distribution; Treatment Outcome; Young Adult | 2009 |
Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules.
Topics: Antineoplastic Agents; Bone Marrow Cells; Camptothecin; Cell Cycle; Cell Proliferation; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Humans; Models, Biological; Neoplasms; Neutropenia; Neutrophils; Stem Cells | 2015 |